# Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40

> **NCT04823052** · PHASE2 · WITHDRAWN · sponsor: **Healx Limited**

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DRUG:** Sulindac (HLX-0201), dose strength 1
- **DRUG:** Sulindac (HLX-0201), dose strength 2
- **DRUG:** Placebo
- **DRUG:** Gaboxadol (HLX-0206)

## Key facts

- **NCT ID:** NCT04823052
- **Lead sponsor:** Healx Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-25
- **Primary completion:** 2022-10-19
- **Final completion:** 2022-10-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Healx has experienced delays to the site activation of the study and this has had an adverse impact on the recruitment timeline which is delaying the progress of other projects in our FXS programme.
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04823052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04823052, "Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04823052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*